Conflict of interest The authors disclose the following relevant interactions with pharmaceutical industry: K. Weller: The author declares that he is or recently was compensated for educational lectures by Essex Pharma (now MSD), Novartis and UCB. N. Schoepke: None. K. Krause: The author declares that she is or recently was compensated for educational lectures by Novartis and Uriach. E. Ardelean: None. M. Bräutigam: The author is employee at Novartis Pharma GmbH. M. Maurer: The author declares that he is or recently was a Speaker and/or Advisor for Almirall Hermal, Essex Pharma, Merckle Recordati, Novartis, Sanofi Aventis, Schering-Plough, MSD, Merck, UCB, and Uriach.
Selected urticaria patients benefit from a referral to tertiary care centres – results of an expert survey
Article first published online: 17 DEC 2011
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 1, pages e8–e16, January 2013
How to Cite
Weller, K., Schoepke, N., Krause, K., Ardelean, E., Bräutigam, M. and Maurer, M. (2013), Selected urticaria patients benefit from a referral to tertiary care centres – results of an expert survey. Journal of the European Academy of Dermatology and Venereology, 27: e8–e16. doi: 10.1111/j.1468-3083.2011.04387.x
Funding sources This work was supported by the Urtikaria Network e.V. (UNEV) and Novartis Pharma. The company did not influence the way of data presentation in this work.
- Issue published online: 18 DEC 2012
- Article first published online: 17 DEC 2011
- Received: 14 July 2011; Accepted: 17 November 2011
- 10Management of chronic spontaneous urticaria in real life – In accordance with the guidelines? A cross-sectional physician based survey study. submitted to J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2011.04370.x [Epub ahead of print]., , et al.
- 24The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol 2009; 23: 1088–1091., , .
- 25High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009; 123: 672–679., , , , .